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Background. It has been suggested that some psychotic symptoms reﬂect ‘aberrant salience’, related to dysfunctional
reward learning. To test this hypothesis we investigated whether patients with schizophrenia showed impaired
learning of task-relevant stimulus–reinforcement associations in the presence of distracting task-irrelevant cues.
Method. We tested 20 medicated patients with schizophrenia and 17 controls on a reaction time game, the Salience
Attribution Test. In this game, participants made a speeded response to earn money in the presence of conditioned
stimuli (CSs). Each CS comprised two visual dimensions, colour and form. Probability of reinforcement varied over
one of these dimensions (task-relevant), but not the other (task-irrelevant). Measures of adaptive and aberrant
motivational salience were calculated on the basis of latency and subjective reinforcement probability rating
diﬀerences over the task-relevant and task-irrelevant dimensions respectively.
Results. Participants rated reinforcement signiﬁcantly more likely and responded signiﬁcantly faster on high-
probability-reinforced relative to low-probability-reinforced trials, representing adaptive motivational salience.
Patients exhibited reduced adaptive salience relative to controls, but the two groups did not diﬀer in terms of
aberrant salience. Patients with delusions exhibited signiﬁcantly greater aberrant salience than those without
delusions, and aberrant salience also correlated with negative symptoms. In the controls, aberrant salience correlated
signiﬁcantly with ‘introvertive anhedonia’ schizotypy.
Conclusions. These data support the hypothesis that aberrant salience is related to the presence of delusions in
medicated patients with schizophrenia, but are also suggestive of a link with negative symptoms. The relationship
between aberrant salience and psychotic symptoms warrants further investigation in unmedicated patients.
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Introduction
Together with direct evidence for dopamine dysregu-
lation in medicated and unmedicated patients with
schizophrenia (Laruelle et al. 1996; Abi-Dargham
et al. 2000; Abi-Dargham, 2004; McGowan et al. 2004),
recent advances in understanding the role of dopa-
mine in reward learning (Wise, 2004; Berridge, 2007)
have rekindled interest in the hypothesis that psy-
chotic symptoms reﬂect the formation of abnormal
stimulus–reinforcement associations, secondary to
aberrant neurotransmission in the ventral striatal
dopamine pathway (Snyder, 1976). Studies in exper-
imental animals have demonstrated that stimuli that
are repeatedly associated with reward, termed con-
ditioned stimuli (CS+), are able to elicit phasic dopa-
mine ﬁring in the midbrain when presented alone,
while stimuli that do not predict reward (CSx) do not
elicit such a response (Schultz et al. 1997). Presentation
of a CS+ has also been shown to increase the speed of
responding relative to the presentation of a CSx,a n
eﬀect that is modulated by ventral striatal dopamine
(Wyvell & Berridge, 2000). This eﬀect has been inter-
preted as reﬂecting adaptive ‘motivational salience’,
meaning that a neutral stimulus becomes imbued
with an emotional quality due to its association with
primary reinforcement, and consequently can inﬂu-
ence behaviour and command attention (Berridge &
Robinson, 1998; Milstein & Dorris, 2007).
A number of theorists have hypothesized that
positive psychotic symptoms may be related to ab-
normal learning of stimulus–reinforcement associ-
ations (King et al. 1984; Miller, 1993; Shaner, 1999).
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ORIGINAL ARTICLEMost recently, Kapur (2003) proposed that the posi-
tive symptoms of schizophrenia may arise out of
‘the aberrant assignment of salience to external objects
and internal representations’, and that antipsychotic
medications reduce positive symptoms, by attenuat-
ing aberrant motivational salience, via blockade of the
dopamine D2 receptor. A corollary of this is that anti-
psychotic medications will also necessarily attenuate
adaptive motivational salience, that is the correct
assignment of salience. This may result not only in
positive symptom remission, but also negative side-
eﬀects related to loss of motivation, such as apathy
and anhedonia.
Despite the implications for understanding the
neurobiological basis of schizophrenia, few studies
have investigated reward learning in schizophrenia.
Studies investigating Pavlovian conditioning in medi-
cated patients found a deﬁcit in learning stimulus–
reinforcement associations (Garmezy, 1952; Cohen,
1956; Waltz et al. 2007) and reduced ventral striatal
responses to CS+ predictive of monetary reward
(Juckel et al. 2006). A recent study reported that
medicated patients with delusions were not only
impaired at learning the predictive value of a CS+
associated with an aversive noise, but also showed
a tendency towards higher galvanic skin responses,
uneasiness ratings and haemodynamic response in
the ventral striatum following the presentation of a
neutral stimulus (Jensen et al. 2008), consistent with
aberrant salience hypothesis.
In order to extend these ﬁndings, here we employed
a novel paradigm, the Salience Attribution Test (SAT),
to quantify adaptive and aberrant salience in patients
with schizophrenia and controls. It has been hypo-
thesized that dopamine antagonists reduce both
adaptive and aberrant salience, and that in the absence
of eﬀective treatment patients with schizophrenia ex-
hibit aberrant salience (Kapur, 2003). Therefore, our
ﬁrst prediction was that that medicated patients with
schizophrenia would exhibit reduced adaptive
salience relative to controls, representing an undesir-
able side-eﬀect of anti-psychotic medication. Our
second prediction was that medicated patients with
schizophrenia would exhibit equivalent aberrant
salience to controls, representing the beneﬁcial eﬀect
of anti-psychotic medication, which is hypothesized
to normalize aberrant salience from a previously
elevated level (Kapur, 2003). Our third prediction was
that those patients with persistent positive symptoms,
in whom medication is not entirely eﬀective, would
exhibit greater aberrant salience than patients without
positive symptoms. Our fourth prediction was that
in the controls, individual diﬀerences in aberrant
salience would be related to the personality trait of
schizotypy, considered to be an index of psychosis
proneness (Chapman et al. 1994; Claridge, 1994;
Stefanis et al. 2004).
Method
Participants
Twenty patients were recruited from a prospective,
longitudinal study of ﬁrst-episode psychosis in West
London, UK (Joyce et al. 2005). Patients were screened
using the World Health Organization Psychosis
Screen (Jablensky et al. 1992) and were recruited if
they were aged 16–50 years. The diagnosis was ascer-
tained using a structured interview, the diagnostic
module of the Diagnostic Interview for Psychosis
(Jablensky et al. 2000). In this longitudinal study, par-
ticipants are contacted 1 and 3 years after presentation
for repeat assessments, at which time the diagnosis
is reviewed. The patients in the present study all
presented with a schizophreniform psychosis and
DSM-IV diagnoses were established or conﬁrmed at
initial assessment (n=1), 1-year (n=14) or 3-year
(n=5) follow-up. The ﬁnal diagnoses were schizo-
phrenia in 19 patients and schizoaﬀective disorder in
the remaining patient.
Three patients were unmedicated at the time of
testing, two were taking ﬁrst-generation drugs (halo-
peridol, ﬂupenthixol), and 15 second-generation drugs
(ﬁve olanzapine, four aripiprazole, two quetiapine,
two risperidone, one clozapine and one a combination
of aripiprazole and quetiapine). Symptom type and
severity were assessed in patients at the time of the
study using the Scales for the Assessment of Positive
Symptoms (SAPS; Andreasen, 1983) and Negative
Symptoms (SANS; Andreasen, 1981), the Calgary
Depression Rating Scale for Schizophrenia (CDRSS;
Addington et al. 1990) and the Young Mania Scale
(YMRS; Young et al. 1978).
These patients were compared with 17 healthy
volunteers, who were recruited by advertisement.
Exclusion criteria were: known psychiatric or neuro-
logical disorder; medical disorder likely to lead to
cognitive impairment; intelligence quotient (IQ) <70;
recent illicit substance use and ﬁrst-degree relatives
diagnosed with a psychotic illness. The absence of
axis-I psychopathology and alcohol- or substance-
abuse/dependence was conﬁrmed with the Mini
International Neuropsychiatric Inventory (Sheehan
et al. 1998). Healthy volunteers completed the short-
form of the Oxford–Liverpool Inventory of Feelings
and Experiences schizotypy questionnaire (O-LIFE;
Mason et al. 2005).
Ethical approval was obtained from the Wands-
worth, Ealing and West London Mental Health
Trust, and National Hospital for Neurology and
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Ethics Committees. All participants provided written
informed consent, were compensated £20 for their
time and travel expenses, and could win up to another
£20 on the SAT.
SAT
On the SAT, participants made a speeded response to
the onset of a probe (a black square) in order to earn
money (see Fig. 1). Pictures that appeared just before
the onset of the probe signalled the probability that the
participant would win money on a given trial, which
occurred on 50% of trials. However, participants
were not informed of the contingencies between the
diﬀerent pictures and reward. Hence, the SAT is rela-
tively straightforward to perform for patients, since it
simply requires participants to respond as quickly
as they can when the probe appears on the screen.
Participants could earn a maximum of £20 on the test
(minimum £5).
Prior to the main test, participants completed a
computerized tutorial, which featured example dis-
plays, written instructions and test trials (see sup-
plementary online materials). Two practice sessions
were embedded into the tutorial to familiarize partici-
pants with the test and provide a measure of baseline
response time (RT). On these practice sessions, a ﬁx-
ation cross appeared at the beginning of each trial.
Following a variable interval (minimum 0.5 s, maxi-
mum 1.5 s) the probe appeared, and participants re-
sponded by pressing a button as quickly as possible.
Participants were instructed to try to respond as
quickly as they were able to, and before the box dis-
appeared. During the ﬁrst practice session the probe
was on the screen for randomized variable periods,
with a maximum duration of 1.5 s, minimum duration
0.5 s and mean duration 1 s. Feedback was provided
after 2 s as ‘Good’ if the participant responded before
the box disappeared, ‘Try to respond faster’ if they
responded after the box disappeared, ‘Too early’ if
they responded before the box appeared, and ‘No key
pressed’ if they did not make a response. On the
second practice session, the mean probe duration was
set to be the mean RT from the ﬁrst, ensuring partici-
pants were responding as quickly as possible and to
yoke task diﬃculty to individual performance. The
standard deviation (S.D.) of the fastest half of the trials
(SDF) was also calculated, and was used to set the
minimum and maximum probe durations for the
second practice session (mean from ﬁrst practice
session¡2rSDF). For the main test, the mean, mini-
mum and maximum probe durations were calculated
from the second practice session in the same way.
No monetary reinforcement was provided during the
practice sessions.
Participants then completed two blocks of 64 trials
on the main test, where money was available on 50%
of trials. The likelihood that money was available on
a trial was signalled by one of four CS that appeared at
the top and bottom of the screen before the onset of the
probe. CSs varied on two diﬀerent visual dimensions:
colour (blue or red) and shape (animal or household
object). Therefore, there were four diﬀerent types of
CS: blue animals; red animals; blue household objects
and red household objects. One of these dimensions
(e.g. colour) was task-relevant so that one level of the
dimension was reinforced on 28 out of 32 (87.5%) of
the trials while only four out of 32 (12.5%) trials of
the other were reinforced. For example, if ‘colour’ was
the reinforced dimensions, 14 out of 16 blue animals
and 14 out of 16 blue household objects would be
reinforced, compared with only two out of 16 red
animals and two out of 16 red household objects.
The other dimension, in this example ‘shape’, was
task-irrelevant, so that 16 out of 32 (50%) of both levels
were reinforced. The contingencies were identical on
the ﬁrst and second blocks of the game. Participants
were not informed of these contingencies, but instead
learned them over the course of the game.
At the beginning of each trial a ﬁxation cross
appeared; after 1000 ms, while the ﬁxation cross re-
mained on-screen, one of the four CSs was displayed
at the top and bottom of the screen and remained on-
screen until the end of the trial. After a variable period
of time (between 0.5 and 1.5 s) the probe appeared
and participants attempted to respond before it
disappeared. The probe duration was calculated
Fixation
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2500 ms
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Fig. 1. The Salience Attribution Test. Participants were required to respond to the black square as quickly as possible. On
50% of trials, participants won more money for quicker responses. The conditioned stimuli appearing before the response
are coloured either red or blue.
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practice block, as described above. After 2.25 s, audi-
tory and visual feedback was presented for 1.5 s (see
Fig. 1). Four diﬀerent versions of the SAT were used,
each with a diﬀerent stimulus feature (blue, red, ani-
mal or household object) reinforced with high prob-
ability. Each participant was administered the same
version for both blocks of the SAT.
If the trial was not reinforced, the message ‘Sorry –
no money available’ was displayed. If the trial was
reinforced, participants won between 5 and 100 pence,
depending on the latency of their response. On re-
inforced trials where participants either made no re-
sponse or responded after the probe had disappeared,
the message ‘Missed: 5 pence’ was displayed. If par-
ticipants responded prematurely (<100 ms after the
onset of the probe), the message displayed was ‘Too
early: 5 pence’. On reinforced trials where partici-
pants responded before the probe disappeared, but
slower than their mean RT, the message ‘Hit – good:
10 pence’ was displayed. When participants re-
sponded more quickly than their mean RT, the
message ‘Quick – very good: X pence’ was displayed
(for responses up to 1.5 SDFs faster than their mean
RT) and ‘Very quick – excellent: X pence’ (for re-
sponses faster than their mean RT by at least 1.5 SDFs).
The reward was scaled according to X=10+90r
(mean RT – trial RT)/(3rSDF), up to a maximum of
100 pence. For example, a response 1 SDF faster than
the mean was reinforced with 40 pence, a response
2 SDFs faster was reinforced with 70 pence, and any
responses 3 SDFs or faster than the mean were re-
inforced with 100 pence. The money won on each trial
was added to the participant’s running total for
that block, Y, which was displayed underneath the
feedback: ‘Total – £Y’. On reinforced trials, a 0.5 s
tone sounded, frequency: (300+(10rX)) Hz. At the
end of each block, participants indicated, using 10 mm
visual analogue scales (VAS), their estimate of the
reinforcement probabilities for each of the four
diﬀerent CSs.
Two measures of motivational salience were calcu-
lated for each block. Adaptive salience was deﬁned
in two ways (behaviourally or implicit and sub-
jectively or explicit). RT adaptive salience (implicit)
was deﬁned as the speeding of responses on high-
probability-reinforcement trials relative to low-
probability-reinforcement trials (collapsing across the
task-irrelevant stimulus dimension), and VAS adapt-
ive salience (explicit) was deﬁned as the increase in
probability rating for high-probability-reinforcement
trials relative to low-probability reinforcement trials
(again, collapsing across the task-irrelevant stimulus
dimension). Aberrant salience was deﬁned as the
absolute diﬀerence in RT (implicit) or VAS rating
(explicit) between the two levels of the task-irrelevant
stimulus dimension (collapsing across the task-
relevant stimulus dimension). Since aberrant salience
is deﬁned as any deviation from equal reaction time
or subjective reinforcement probability rating for the
two levels of the task-irrelevant stimulus dimension,
the sign is unimportant. Therefore aberrant salience
was always positive, whereas adaptive salience could
be positive or negative. The number of premature
responses and omissions were also recorded for each
stimulus type on each block.
Other cognitive tests
To assess whether any abnormalities on the SAT
might be related to neurocognitive impairments in
the patient group, pre-morbid IQ was estimated
using the Wechsler Test of Adult Reading (WTAR;
Wechsler, 2001) and working memory with the for-
wards and backwards digit-span (Wechsler, 1981). To
assess whether aberrant salience might be related
to the ‘jumping to conclusions’ bias previously re-
ported in schizophrenia (Garety et al. 1991), a 60:40
version of the Beads Task (Garety et al. 1991) was in-
cluded. Data on the Beads Task were not collected
for one control.
Statistical analysis
All data were analysed using the Statistical Package
for the Social Sciences, version 15 (SPSS Inc., Chicago,
IL, USA). Demographic data and data from the Beads
Task were analysed using independent samples t tests
and x
2 tests. SAT and digit-span data were analysed
using repeated-measures analysis of variance. For
digit-span, stage (forwards/backwards for digit-span)
was the within-subjects variable, while on the SAT
block (1/2) was the within-subjects variable. Group
(patient/control) was the between-subjects variable
in both analyses. RT and VAS aberrant salience scores
from the SAT were square root-transformed prior to
analysis to reduce skew, though untransformed values
are presented in the text, ﬁgures and tables for clarity.
To determine whether participants consistently as-
signed aberrant salience to any particular stimulus
feature, x
2 tests were employed.
To investigate the hypothesis that aberrant salience
was related to positive symptoms of schizophrenia,
we divided the patients into those with and without
positive symptoms when analysing SAT data. This
grouping was performed on the basis of the sum of
the global scores on the SAPS, either zero (no positive
symptoms) or greater than zero (positive symptoms).
We carried out a similar procedure using the SANS
to investigate the eﬀect of negative symptoms. In both
202 J. P. Roiser et al.cases, symptom group was entered as the between-
subjects variable.
Correlations with O-LIFE subscales and clinical
variables were performed using Pearson’s r,o r
Spearman’s r if the residuals from the parametric
correlation were not normally distributed. For all
analyses a p value of <0.05 was considered signiﬁcant
while 0.05 <p<0.1 was considered as a trend towards
signiﬁcance.
Results
Demographic data
Patients and controls were well matched for gender
distribution, age and pre-morbid IQ (see Table 1).
Within the patients, the symptom subgroups were
well matched for demographic variables (data not
shown).
SAT
Reaction time (implicit salience)
Behavioural data are presented in Table 2. Participants
responded more quickly on high- relative to low-
probability-reinforced trials [RT adaptive salience:
F(1,35)=9.5, p=0.004, partial g
2=0.213]. Consistent
with our ﬁrst prediction, controls exhibited greater RT
adaptive salience than patients [grouprprobability
interaction: F(1,35)=4.8, p=0.035, partial g
2=0.121].
Controls exhibited signiﬁcant RT adaptive salience
[F(1,16)=9.8, p=0.007, partial g
2=0.379], but patients
did not (F<1, partial g
2=0.030) (see Fig. 2). There was
no main eﬀect of block or group on RT, and no other
interactions approached signiﬁcance (p>0.1). Patients
and controls did not diﬀer in terms of RT aberrant
salience (F<1, partial g
2<0.001), and the main eﬀect
of block and grouprblock interaction were both
non-signiﬁcant (p>0.1). Participants did not reliably
respond more quickly in the context of any particular
irrelevant stimulus feature relative to the other
(p>0.05 for all).
VAS (explicit salience)
Participants rated high-probability-reinforced trials
as more likely to yield reward than low-probability-
reinforced trials [VAS adaptive salience: F(1,35)=
54.3, p<0.001, partial g
2=0.608]. Again, consistent
with our ﬁrst prediction, controls exhibited greater
VAS adaptive salience than patients [groupr
probability interaction: F(1,35)=10.9, p=0.002, par-
tial g
2=0.238], though VAS adaptive salience was
signiﬁcant in both groups [controls: F(1,16)=71.9,
p<0.001, partial g
2=0.818; patients: F(1,19)=7.3,
p=0.014, partial g
2=0.279] (see Fig. 3). There was no
main eﬀect of block or group on VAS rating, and no
other interactions approached signiﬁcance (p>0.1).
Consistent with our second prediction, patients
and controls did not diﬀer in terms of VAS aberrant
salience (F<1, partial g
2=0.005), though controls
reduced aberrant salience from block 1 to block 2
[F(1,16)=7.8, p=0.013] while patients did not (F<1)
[grouprblock interaction: F(1,35)=7.0, p=0.012].
RT and VAS aberrant salience were uncorrelated
across subjects (p>0.2). Participants did not reliably
rate any particular irrelevant stimulus feature as more
Table 1. Demographic measures
Controls Patients Statistic
Age, years 25.2 (7.4) 27.0 (7.0) t(35) <1
Gender (male/female) 7/10 11/9 x
2(1) <1
Estimated full scale IQ (WTAR) 97.8 (10.3) 92.7 (12.1) t(35)=1.4, p>0.1
O-LIFE unusual experiences 3.1 (2.8)
O-LIFE cognitive disorganization 3.5 (2.9)
O-LIFE introvertive anhedonia 1.6 (1.9)
O-LIFE impulsive non-conformity 1.8 (1.6)
SAPS sum of global subscale scores 4.9 (5.3)
SANS sum of global subscale scores 5.4 (6.0)
Calgary depression rating scale score 4.2 (5.5)
Young mania rating scale score 1.4 (4.1)
IQ, Intelligence quotient; WTAR, Wechsler Test of Adult Reading; O-LIFE,
Oxford–Liverpool Inventory of Feelings and Experiences; SAPS, Scale for the
Assessment of Positive Symptoms; SANS, Scale for the Assessment of Negative
Symptoms.
Values are given as mean (standard deviation).
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other (p>0.05 for all).
Eﬀect of symptoms of schizophrenia and schizotypy on
aberrant salience
Consistent with our third prediction, patients with
positive symptoms [n=13, mean sum of SAPS global
scores 7.5 (S.D.=4.8)] exhibited signiﬁcantly greater
VAS aberrant salience than those without (n=7)
[t(18)=3.2, p=0.005, Cohen’s d=1.6]. Positive symp-
toms showed a trend towards correlating with VAS
aberrant salience (rho=0.40, p=0.085). This eﬀect
appeared to be driven by the presence of delusions
and not hallucinations. Delusional patients [n=13,
mean SAPS global delusions score 3.2 (S.D.=1.0) out
Table 2. Behavioural data
Test Measure Controls Patients
Salience Attribution Test
Block 1 RT high probability (ms) 247.5 (22.4) 281.4 (82.0)
RT low probability (ms) 262.9 (28.9) 285.3 (86.6)
RT adaptive salience (ms)a 15.4 (24.7) 3.9 (18.7)
RT irrelevant ‘high’ (ms)b 247.0 (23.3) 276.3 (83.4)
RT irrelevant ‘low’ (ms)b 263.5 (22.9) 290.4 (85.9)
RT aberrant salience (ms)c 16.5 (10.3) 14.2 (12.4)
VAS high probability (mm) 65.1 (15.4) 53.5 (15.7)
VAS low probability (mm) 26.2 (16.6) 35.3 (20.4)
VAS adaptive salience (mm)a 38.9 (28.5) 18.2 (32.8)
VAS irrelevant ‘high’ (mm)b 55.1 (10.6) 51.2 (12.0)
VAS irrelevant ‘low’ (mm)b 36.1 (8.9) 37.7 (9.6)
VAS aberrant salience (mm)c 19.0 (13.2) 13.5 (15.2)
Block 2 RT high probability (ms) 246.6 (23.4) 289.1 (87.8)
RT low probability (ms) 254.6 (31.0) 289.1 (85.3)
RT adaptive salience (ms)a 8.2 (18.6) 0.1 (19.4)
RT irrelevant ‘high’ (ms)b 243.4 (23.9) 278.8 (81.8)
RT irrelevant ‘low’ (ms)b 257.9 (30.3) 299.3 (91.4)
RT aberrant salience (ms)c 14.5 (14.9) 20.5 (24.2)
VAS high probability (mm) 70.0 (14.1) 51.7 (21.2)
VAS low probability (mm) 18.9 (15.7) 35.5 (18.7)
VAS adaptive salience (mm)a 51.0 (21.2) 16.1 (32.8)
VAS irrelevant ‘high’ (mm)b 49.9 (11.1) 51.5 (13.6)
VAS irrelevant ‘low’ (mm)b 39.1 (11.6) 35.9 (13.6)
VAS aberrant salience (mm)c 10.8 (8.7) 15.6 (14.7)
Digit span Forwards 8.8 (2.1) 7.5 (2.2)
Backwards 5.4 (2.6) 5.4 (1.8)
Beads test Number of beads viewed 9.3 (2.9) 8.9 (5.3)
Conﬁdence rating (%) 69.1 (11.6) 55.1 (27.9)
Correct guess (% of sample) 87.5 65.0
RT, Reaction time; VAS, visual analogue scale.
Values are given as mean (standard deviation).
aWe deﬁned adaptive salience as quicker responding to or higher subjective reinforcement probability rating for 90%
(high) probability-reinforcement trials relative to 10% (low) probability-reinforcement trials. For RT, adaptive salience is
computed as: low reinforcement probability mean RT – high reinforcement probability mean RT. For VAS, adaptive salience
is computed as: high reinforcement probability VAS rating – low reinforcement probability VAS rating.
bWe deﬁned, for each subject, ‘high’ and ‘low’ irrelevant levels on the task-irrelevant stimulus dimension based on their
responses: for RT, ‘high’ denotes whichever level participants responded faster to; for VAS, ‘high’ denotes whichever
level participants rated as more likely to result in reinforcement. This calculation was performed separately for each block.
cWe deﬁned aberrant salience as quicker responding to or higher subjective reinforcement probability rating for one level
of the task-irrelevant stimulus dimension relative to the other level (see b above). For RT, aberrant salience is computed as:
irrelevant ‘low’ RT – irrelevant ‘high’ RT. For VAS, aberrant salience is computed as: irrelevant ‘high’ VAS rating – irrelevant
‘low’ VAS rating.
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greater VAS aberrant salience than those with no
delusions (n=7) [t(18)=3.2, p=0.005, Cohen’s d=1.6]
(see Fig. 4). VAS aberrant salience correlated signiﬁ-
cantly with SAPS global delusions score (r=0.5,
p=0.025). Interestingly, patients with no delusions
actually exhibited signiﬁcantly less VAS aberrant
salience than controls [t(22)=3.0, p=0.007]. However,
there was no diﬀerence in VAS aberrant salience
between patients with hallucinations [n=9, mean
SAPS global hallucinations score 3.9 (S.D.=1.4)] and
those without (n=11) (t=1.3, p=0.21, Cohen’s d=0.6).
Patients with positive symptoms did not diﬀer from
those with no positive symptoms on VAS adaptive
salience [delusions: 16.7 (S.D.=28.4 mm); no delu-
sions: 17.3 (S.D.=29.4) mm, t(18)=0.05, p=0.96].
Surprisingly, patients with negative symptoms
[n=12, mean sum of SANS global scores 8.9
(S.D.=5.1)] exhibited signiﬁcantly greater VAS ab-
errant salience than those without (n=8) (t(18)=3.5,
p=0.003, Cohen’s d=1.6). Interestingly, patients with
no negative symptoms exhibited signiﬁcantly less
VAS aberrant salience than controls [t(23)=3.1,
p=0.006]. Negative symptoms correlated signiﬁcantly
with VAS aberrant salience (r=0.51, p=0.020) (see
Fig. 5). Negative symptoms also showed a trend
towards correlating negatively with VAS adaptive
salience (r=–0.42, p=0.068), though patients with
negative symptoms did not diﬀer signiﬁcantly from
those without negative symptoms on VAS adaptive
salience [no negative symptoms: 28.6 (S.D.=25.2) mm;
negative symptoms: mean 9.5 (S.D.=28.5) mm, t(18)=
1.5, p=0.14].
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Fig. 2. Adaptive salience based on latency in patients with
schizophrenia and controls. * Patients exhibited reduced
adaptive salience relative to controls (p=0.035). Values are
means and standard errors.
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Fig. 3. Adaptive salience based on subjective reinforcement
probability ratings in patients with schizophrenia and
controls. * Patients exhibited reduced adaptive salience
relative to controls (p=0.002). Values are means and
standard errors.
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Fig. 4. Aberrant salience calculated from subjective
reinforcement probability ratings in patients with
schizophrenia. * Patients with delusions exhibited
signiﬁcantly greater aberrant salience than those without
delusions (p=0.005). Values are means and standard errors.
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Fig. 5. Relationship between the sum of global scores
from the Scale for the Assessment of Negative Symptoms
(SANS) and aberrant salience (calculated from subjective
reinforcement probability ratings). Aberrant salience
correlated signiﬁcantly with negative symptoms in patients
with schizophrenia (r=0.51, p=0.020).
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the patients (r=0.50, p=0.027). However, the diﬀer-
ence in VAS aberrant salience between patients with
and without positive symptoms remained signiﬁcant
when negative symptoms were included as a covariate
[F(1,17)=5.5, p=0.032], and the diﬀerence in VAS
aberrant salience between patients with and without
negative symptoms remained signiﬁcant when posi-
tive symptoms were included as a covariate [F(1,17)=
10.5, p=0.005]. YMRS and CDRSS score were not
correlated with either adaptive or aberrant salience.
Consistent with our fourth prediction, within the
controls, score on the introvertive anhedonia subscale
of the O-LIFE correlated negatively with RT adaptive
salience (r=–0.63, p=0.007) and VAS adaptive
salience (r=–0.62, p=0.008), positively with VAS ab-
errant salience (r=0.49, p=0.045) and showed a trend
towards correlating positively with RT aberrant
salience (r=0.42, p=0.092). The cognitive disorgan-
ization subscale of the O-LIFE also showed a trend
towards correlating with RT aberrant salience (r=0.45,
p=0.073).
Premature responses and omissions
Other than trends towards making more premature
responses [F(1,35)=3.0, p=0.092] and fewer omis-
sions [F(1,32)=3.9, p=0.057] on high-probability-
relative to low-probability-reinforcement trials, analy-
sis of errors identiﬁed no main eﬀects or interactions
approaching signiﬁcance.
Other behavioural data
Analysis of Beads Test and digit-span data revealed no
group diﬀerences or interactions with group (p>0.1),
other than a trend towards greater conﬁdence ratings
on the Beads Test in controls than patients [t(26.5)=
2.1, p=0.052]. Across all participants, VAS adaptive
salience correlated signiﬁcantly with WTAR (r=0.36,
p=0.030), forwards digit-span (r=0.42, p=0.010) and
backwards digit-span (r=0.43, p=0.009). RT aberrant
salience was negatively correlated with WTAR
(r=x0.341, p=0.039). However, Beads Task per-
formance was uncorrelated with adaptive or aberrant
salience on the SAT.
Discussion
To our knowledge, this is the ﬁrst study to demon-
strate a relationship between the presence of delusions
and abnormal attribution of salience in schizophrenia.
Thus, although the schizophrenia group as a whole
exhibited equivalent aberrant salience to controls,
patients with delusions demonstrated signiﬁcantly
more aberrant salience than those without. In con-
cordance with other studies (Waltz et al. 2007; Jensen
et al. 2008), we also found impaired learning of
stimulus–reinforcement associations (indexed by a
reduction in adaptive salience) in medicated patients
with schizophrenia, which we hypothesize is related
to dopamine D2 receptor blockade (Cutmore &
Beninger, 1990).
Aberrant salience and positive symptoms of
schizophrenia
One explanation of increased aberrant salience in
patients with positive symptoms concerns aberrant
dopamine signalling. Contemporary accounts of re-
ward learning suggest that phasic dopamine ﬁring
codes reward prediction errors (Schultz et al. 1997),
for example, those arising from temporal diﬀerence
models of reinforcement learning (Dayan & Balleine,
2002). Such models elegantly account for changes
in both the ﬁring patterns of ventral tegmental area
dopamine neurons in monkeys (Schultz, 1997), and
ventral striatal responses in humans (Pessiglione
et al. 2006; Seymour et al. 2007), as reward-learning
progresses. If phasic dopamine release signals re-
inforcement prediction errors, any large stochastic
ﬂuctuation in dopamine release may disrupt learning
about stimulus–reinforcement associations, generat-
ing a state in which motivational salience could be
misattributed to neutral stimuli, or what might
be termed a ‘false-positive’ phasic dopamine signal;
such events have been proposed to result in positive
symptoms (Kapur, 2003).
In the present study, patients for whom medication
had eﬀectively eliminated positive symptoms actually
exhibited signiﬁcantly less aberrant salience than
controls, supporting the hypothesis that the beneﬁcial
eﬀects of antipsychotic medications on positive
symptoms are related to their ability to dampen-down
aberrant salience (Kapur, 2003). However, indepen-
dent of symptoms at the time of testing, the patients
with schizophrenia exhibited signiﬁcantly less adapt-
ive salience than controls. Antipsychotic medication
has long been considered to exacerbate negative
symptoms in schizophrenia, which may be related to
reduced adaptive salience [see discussion below and
Schooler (1994)]. Our ﬁndings support the suggestion
of Kapur (2003) that this may be a necessary corollary
to the beneﬁcial eﬀect of antipsychotic medication on
positive symptoms.
Previous studies suggest that antipsychotic medi-
cation does not necessarily normalize abnormal
dopamine signalling in psychotic patients. For ex-
ample, functional neuroimaging studies have shown
dopamine dysregulation in both medicated and
206 J. P. Roiser et al.unmedicated patients (Hietala et al. 1995; Abi-
Dargham, 2004; McGowan et al. 2004). Therefore
persistent symptoms in medicated patients might
still be related to aberrant salience. Furthermore, the
only other study investigating stimulus–reinforcement
learning for appetitive outcomes in psychosis found
that both medicated and unmedicated patients re-
sponded more quickly to a CSx than controls, a
ﬁnding interpreted as aberrant salience (Murray et al.
2008). This study also reported that patients exhibited
reduced haemodynamic correlates of reward predic-
tion errors in the ventral striatum relative to controls,
consistent with other ﬁndings in medicated patients
(Juckel et al. 2006; Jensen et al. 2008). Nevertheless
it will be important to conﬁrm our ﬁndings in
unmedicated patients.
Aberrant salience and negative symptoms of
schizophrenia
Although positive symptoms were associated with
increased aberrant salience, our data also suggest a
link between aberrant salience and negative symp-
toms. Aberrant salience correlated not only with
negative symptoms in the patients, but also with
O-LIFE introvertive anhedonia, which relates to re-
duced interest and social withdrawal, in the controls.
If dopamine transmission is dysregulated in psychosis
(Abi-Dargham, 2004), it is possible that ‘false nega-
tives’ in the phasic dopamine signal might occur, i.e.
a reinforcement-related stimulus fails to elicit a suﬃ-
ciently large phasic dopamine response. False nega-
tives would decrease the value of motivationally
salient stimuli, possibly leading to symptoms such as
avolition, apathy and social withdrawal. Consistent
with this explanation, other studies that investigated
responses to emotionally salient images in medicated
patients with schizophrenia reported decreased re-
sponding for (Heerey & Gold, 2007) and ventral stria-
tal responses to (Taylor et al. 2005) positive emotional
stimuli relative to controls.
This explanation is also consistent with data from
a functional magnetic resonance imaging study
investigating the eﬀects of d-amphetamine on reward
processing in healthy volunteers. Knutson et al. (2004)
found that amphetamine administration paradoxically
decreased the magnitude of phasic ventral striatal
haemodynamic responses in response to a CS+ that
signalled reward (i.e. increasing the potential for a
false negative). In the same study, amphetamine ad-
ministration caused signiﬁcant phasic haemodynamic
responses in the ventral striatum following CS+ that
signalled potential monetary loss, an eﬀect that
was absent under placebo, possibly reﬂecting a loss of
speciﬁcity of dopamine signalling (i.e. increasing the
potential for a false positive). The aberrant salience
model might therefore explain both positive and
negative symptoms by appealing to a common neuro-
biological mechanism, namely a loss of signal:noise
ratio in the mesolimbic dopamine system, possibly as
a result of increased tonic dopamine activity (Grace,
1991; Winterer & Weinberger, 2004).
Study limitations and potential improvements
Though these results broadly support the aberrant
salience hypothesis, some limitations of the study
merit comment. We tested a relatively small sample
of patients with schizophrenia and performed multi-
ple statistical comparisons, raising the likelihood of
type I error. Therefore, these results should be treated
with caution until replicated. Further, it is possible
that the ﬁnding of reduced adaptive salience in the
patients might simply reﬂect a learning deﬁcit inde-
pendent of reward, or perhaps a diﬃculty in using in-
formative cues to guide speeded responses (Robbins,
2005), which could be related either to the illness or
the eﬀects of antipsychotic medication (Pessiglione
et al. 2006). However, such explanations cannot ex-
plain diﬀerences in our measure of aberrant salience
between symptom subgroups, or the correlation with
schizotypy in the healthy volunteers.
It is possible that the diﬀerences in aberrant salience
between the patients with and without delusions
might also be explained by non-speciﬁc cognitive
impairments in symptomatic patients, since such im-
pairments might result in a failure to understand the
task, diﬃculty in representing probabilities or a gen-
eral tendency to respond more randomly. However,
we consider this explanation unlikely for two reasons.
First, the patients with and without delusions did not
diﬀer in terms of VAS adaptive salience, suggesting
that they were equally able to learn and report the
diﬀerence in reinforcement probability between the
two levels of the task-relevant stimulus dimension,
albeit to a lesser extent than controls. Second, the
patients with and without delusions performed simi-
larly on WTAR IQ, forwards and the backwards digit-
span tasks and the Beads Task, making an explanation
in terms of non-speciﬁc deﬁcits less likely.
Summary
In summary, these data are consistent with the hypo-
thesis that schizophrenia patients with delusions
exhibit aberrant salience. However, negative symp-
toms were also correlated with our measures of both
adaptive and aberrant salience. The aberrant salience
hypothesis warrants further investigation in unmedi-
cated patients with schizophrenia.
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